ArticlePloS one2012
Tumor volume as an alternative response measurement for imatinib treated GIST patients.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Temporal Trends in Vulvar Cancer Cases and Associated Factors of Adverse Clinical Features: A 6-year Retrospective Study From a Tertiary Hospital in Indonesia.International journal of women's health · 2026Article
- Hidden risk factors for recurrence of jejunoileal Gastrointestinal stromal tumors with low NIH classification: implications for surveillance and adjuvant therapy.Journal of translational medicine · 2025Article
- Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories.Radiology advances · 2025Article
- Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer.NPJ precision oncology · 2024Article
- Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.Molecular oncology · 2024Article
- Monitoring neoadjuvant treatment-induced surgical benefit in GIST patients using CT-based radiological criteria.Surgery open science · 2024Article
- Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.Molecular cancer therapeutics · 2024Article
- RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment.Radiology. Imaging cancer · 2023Article
- Predictive power of deep-learning segmentation based prognostication model in non-small cell lung cancer.Frontiers in oncology · 2023Article
- Early Prediction and Monitoring of Treatment Response in Gastrointestinal Stromal Tumors by Means of Imaging: A Systematic Review.Diagnostics (Basel, Switzerland) · 2022Review
- Optimized scaling of translational factors in oncology: from xenografts to RECIST.Cancer chemotherapy and pharmacology · 2022Article
- Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.Therapeutic advances in medical oncology · 2022Article
- Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume.Frontiers in oncology · 2022Article
- The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2021Article
- Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.Cancer medicine · 2021Article
- CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1.Radiology. Imaging cancer · 2021Article
- Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial.Journal of veterinary internal medicine · 2021Article
- Article
- Correlation between Three-Dimensional Volume and Malignant Potential of Gastrointestinal Stromal Tumors (GISTs).Journal of clinical medicine · 2020Article
- Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis.ERJ open research · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessment of tumor size changes is crucial in clinical trials and patient care. We compared imatinib-induced volume changes of liver metastases (LM) from gastro-intestinal stromal tumors (GIST) to RECIST and Choi criteria and their association with overall survival (OS).
methodsLM from 84 GIST patients (training and validation set) were evaluated using manual and semi-automated Computed Tomography measurements at baseline, after 3, 6 and 12 months of imatinib. The ability of uni-dimensional (1D) and three-dimensional (3D) measurements to detect size changes (increase/decrease) ≥20% was evaluated. Volumetric response cut-offs were derived from minimally relevant changes (+20/-30%) by RECIST, considering lesions as spherical or ellipsoidal.
results3D measurements detected size changes ≥20% more frequently than 1D at every time-point (P≤0.008). 3D and Choi criteria registered more responses than RECIST at 3 and 6 months for 3D-spheres (P≤0.03) and at all time-points for 3D-ellipsoids and Choi criteria (P<0.001). Progressive disease by 3D criteria seems to better correlate to OS at late time-points than other criteria.
conclusionVolume criteria (especially ellipsoids) classify a higher number of patients as imatinib-responders than RECIST. Volume discriminates size changes better than diameter in GIST and constitutes a feasible and robust method to evaluate response and predict patient benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.